{"id":484499,"date":"2021-04-29T09:05:48","date_gmt":"2021-04-29T13:05:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/"},"modified":"2021-04-29T09:05:48","modified_gmt":"2021-04-29T13:05:48","slug":"nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/","title":{"rendered":"Nephria Bio signs exclusive agreement with Drexel University to license new &#8220;MXene&#8221; nanomaterial for future dialysis innovations"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>Nephria Bio secures a key technology needed to develop wearable dialysis therapies <\/li>\n<li>Nephria is in close collaboration with EOFlow and Dr. <span class=\"xn-person\">Yury Gogotsi&#8217;s<\/span> lab at <span class=\"xn-org\">Drexel University<\/span><\/li>\n<\/ul>\n<p>PORTMOUTH, N.H., <span class=\"xn-chron\">April 29, 2021<\/span> \/PRNewswire\/ &#8212; <b><u>On <span class=\"xn-chron\">April 29<\/span>, Nephria Bio, a privately held US corporation specializing in the development of innovative approaches to dialysis, announced that it signed a license agreement with <span class=\"xn-org\">Drexel University<\/span> to transfer technology of new MXene nanomaterials.<\/u><\/b><\/p>\n<p>Through this license agreement, Nephria Bio, Inc. (&#8216;Nephria Bio&#8217;) obtained the exclusive rights to use MXenes, invented and developed by Dr. <span class=\"xn-person\">Yury Gogotsi<\/span>, PhD, Distinguished University and Bach professor in <span class=\"xn-org\">Drexel&#8217;s<\/span> College of Engineering who is a world leader in developing and studying MXenes. Nephria Bio plans to develop more efficient cartridges for dialysis centers and wearable dialysis devices with this technology transfer.<\/p>\n<p>Nephria Bio is a privately held US corporation spun out of EOFlow Co., Ltd. (&#8220;EOFlow&#8221;), a public medical device company based in <span class=\"xn-location\">South Korea<\/span>, to address current challenges to dialysis treatment for renal patients through innovations aimed at more effective in-center and home-based dialysis treatment, as well as building wearable solutions.<\/p>\n<p>MXenes are inorganic nanomaterials with two-dimensional (2D) properties. MXenes are attracting increasing attention along with graphene as an ideal 2D material. The advantages of MXenes are numerous but include superior biocompatibility, sieving coefficient and higher urea binding affinity, all properties which make them an ideal fit for application to dialysis. Although there has been a lot of research of MXene application in the energy related and other applications, this will be the first time that MXene is applied to dialysis.<\/p>\n<p>Nephria Bio is developing a flexible, wearable, cartridge-based system, termed EOCARRT<sup>TM<\/sup> (EOPump-based Continuous Ambulatory Renal Replacement Therapy), which allows ambulatory dialysis. The system could supplement\/bridge traditional dialysis therapy and, ultimately, supplant it, depending upon device performance and therapeutic needs.<\/p>\n<p>Once more efficient cartridges and wearable dialysis therapies\u00a0are developed, high demand in the market is expected. Global dialysis market reached <span class=\"xn-money\">$90.3 billion<\/span> in 2019, and is estimated to reach <span class=\"xn-money\">$177.6 billion<\/span> by 2027, with the increase projected to be due in large measure to increases in the number of hypertensive and diabetic patients ultimately requiring dialysis. On the other hand, there are no such products as wearable artificial kidneys commercially available yet.<\/p>\n<p>Nephria Bio is working closely with Dr. <span class=\"xn-person\">Yury Gogotsi&#8217;s<\/span> laboratory to optimize the MXene formulation. The company is also in close collaboration with its founding company, EOFlow, to adapt the electroosmotic pump (EOP) platform developed initially for wearable drug delivery applications to wearable dialysis therapy. <\/p>\n<p>In developing the EOCARRT, technologies which are essential to developing an effective wearable dialysis solution have been brought together; a small, lightweight pumping technology with low power consumption, and a high efficiency filter technology, enabling reuse and recycling of dialysate.<\/p>\n<p>&#8220;Two technologies are essential to develop wearable artificial kidneys; One is a small, light actuator with low power consumption, and the other is an efficient material for urea filtration. Nephria Bio secured them both- the proprietary electroosmotic pump technology from EOFlow, and the filter technology from <span class=\"xn-org\">Drexel University<\/span>,&#8221; <span class=\"xn-person\">Jesse Kim<\/span>, founding CEO of Nephria Bio said.<\/p>\n<p>&#8220;With the unique combination of these enabling technologies, Nephria Bio feels that it can substantially enhance dialysis therapy for kidney patients.&#8221;<\/p>\n<p>&#8220;Our fundamental study of titanium carbide MXene, supported by the U.S. National Science Foundation, showed that MXene is biocompatible, able of adsorbing a variety of small molecules, and holds a lot of promise in medical applications, so it is exciting to see it applied for improving and really changing dialysis \u2014 an area of need in health care that can help millions of people,&#8221; Gogotsi said.<\/p>\n<p>&#8220;This work could give hundreds of thousands of people with kidney disease the ability to live life more freely and fully,&#8221; said <span class=\"xn-person\">Meera Harhay<\/span>, MD, an associate professor of Medicine in <span class=\"xn-org\">Drexel&#8217;s<\/span> College of Medicine, who has been working with Gogotsi to study MXene&#8217;s application in dialysis. &#8220;A wearable artificial kidney would allow people suffering from kidney disease to more easily work and travel and maintain a more active lifestyle, which has been associated with positive health outcomes.&#8221;<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN60032&amp;sd=2021-04-29\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations-301279812.html\">http:\/\/www.prnewswire.com\/news-releases\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations-301279812.html<\/a><\/p>\n<p>SOURCE  Nephria Bio, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CN60032&amp;Transmission_Id=202104290900PR_NEWS_USPR_____CN60032&amp;DateId=20210429\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Nephria Bio secures a key technology needed to develop wearable dialysis therapies Nephria is in close collaboration with EOFlow and Dr. Yury Gogotsi&#8217;s lab at Drexel University PORTMOUTH, N.H., April 29, 2021 \/PRNewswire\/ &#8212; On April 29, Nephria Bio, a privately held US corporation specializing in the development of innovative approaches to dialysis, announced that it signed a license agreement with Drexel University to transfer technology of new MXene nanomaterials. Through this license agreement, Nephria Bio, Inc. (&#8216;Nephria Bio&#8217;) obtained the exclusive rights to use MXenes, invented and developed by Dr. Yury Gogotsi, PhD, Distinguished University and Bach professor in Drexel&#8217;s College of Engineering who is a world leader in developing and studying MXenes. Nephria Bio plans to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nephria Bio signs exclusive agreement with Drexel University to license new &#8220;MXene&#8221; nanomaterial for future dialysis innovations&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-484499","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nephria Bio signs exclusive agreement with Drexel University to license new &quot;MXene&quot; nanomaterial for future dialysis innovations - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nephria Bio signs exclusive agreement with Drexel University to license new &quot;MXene&quot; nanomaterial for future dialysis innovations - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Nephria Bio secures a key technology needed to develop wearable dialysis therapies Nephria is in close collaboration with EOFlow and Dr. Yury Gogotsi&#8217;s lab at Drexel University PORTMOUTH, N.H., April 29, 2021 \/PRNewswire\/ &#8212; On April 29, Nephria Bio, a privately held US corporation specializing in the development of innovative approaches to dialysis, announced that it signed a license agreement with Drexel University to transfer technology of new MXene nanomaterials. Through this license agreement, Nephria Bio, Inc. (&#8216;Nephria Bio&#8217;) obtained the exclusive rights to use MXenes, invented and developed by Dr. Yury Gogotsi, PhD, Distinguished University and Bach professor in Drexel&#8217;s College of Engineering who is a world leader in developing and studying MXenes. Nephria Bio plans to &hellip; Continue reading &quot;Nephria Bio signs exclusive agreement with Drexel University to license new &#8220;MXene&#8221; nanomaterial for future dialysis innovations&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-29T13:05:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN60032&amp;sd=2021-04-29\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nephria Bio signs exclusive agreement with Drexel University to license new &#8220;MXene&#8221; nanomaterial for future dialysis innovations\",\"datePublished\":\"2021-04-29T13:05:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\\\/\"},\"wordCount\":710,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN60032&amp;sd=2021-04-29\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\\\/\",\"name\":\"Nephria Bio signs exclusive agreement with Drexel University to license new \\\"MXene\\\" nanomaterial for future dialysis innovations - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN60032&amp;sd=2021-04-29\",\"datePublished\":\"2021-04-29T13:05:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN60032&amp;sd=2021-04-29\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN60032&amp;sd=2021-04-29\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nephria Bio signs exclusive agreement with Drexel University to license new &#8220;MXene&#8221; nanomaterial for future dialysis innovations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nephria Bio signs exclusive agreement with Drexel University to license new \"MXene\" nanomaterial for future dialysis innovations - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/","og_locale":"en_US","og_type":"article","og_title":"Nephria Bio signs exclusive agreement with Drexel University to license new \"MXene\" nanomaterial for future dialysis innovations - Market Newsdesk","og_description":"PR Newswire Nephria Bio secures a key technology needed to develop wearable dialysis therapies Nephria is in close collaboration with EOFlow and Dr. Yury Gogotsi&#8217;s lab at Drexel University PORTMOUTH, N.H., April 29, 2021 \/PRNewswire\/ &#8212; On April 29, Nephria Bio, a privately held US corporation specializing in the development of innovative approaches to dialysis, announced that it signed a license agreement with Drexel University to transfer technology of new MXene nanomaterials. Through this license agreement, Nephria Bio, Inc. (&#8216;Nephria Bio&#8217;) obtained the exclusive rights to use MXenes, invented and developed by Dr. Yury Gogotsi, PhD, Distinguished University and Bach professor in Drexel&#8217;s College of Engineering who is a world leader in developing and studying MXenes. Nephria Bio plans to &hellip; Continue reading \"Nephria Bio signs exclusive agreement with Drexel University to license new &#8220;MXene&#8221; nanomaterial for future dialysis innovations\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-29T13:05:48+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN60032&amp;sd=2021-04-29","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nephria Bio signs exclusive agreement with Drexel University to license new &#8220;MXene&#8221; nanomaterial for future dialysis innovations","datePublished":"2021-04-29T13:05:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/"},"wordCount":710,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN60032&amp;sd=2021-04-29","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/","name":"Nephria Bio signs exclusive agreement with Drexel University to license new \"MXene\" nanomaterial for future dialysis innovations - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN60032&amp;sd=2021-04-29","datePublished":"2021-04-29T13:05:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN60032&amp;sd=2021-04-29","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN60032&amp;sd=2021-04-29"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nephria-bio-signs-exclusive-agreement-with-drexel-university-to-license-new-mxene-nanomaterial-for-future-dialysis-innovations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nephria Bio signs exclusive agreement with Drexel University to license new &#8220;MXene&#8221; nanomaterial for future dialysis innovations"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/484499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=484499"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/484499\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=484499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=484499"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=484499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}